Chimerix Announces Second Quarter 2017 Financial Results

DURHAM, N.C., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today reported financial results and provided a corporate update for the second quarter ended June 30, 2017.

“Throughout the second quarter, we continued to make steady progress as we advance brincidofovir for the benefit of immunocompromised patients,” said M. Michelle Berrey, MD, MPH, President and Chief Executive Officer of Chimerix. “We are pleased by the enrollment in our multiple ascending dose study of IV BCV, the results of which will inform the next phase of development.”

“Our efforts in the first half of 2017 position us to achieve important milestones throughout the remainder of the year. We look forward to data from AdVance, our study of the natural history and outcomes of AdV infection in HCT recipients in Europe, including the use of off-label agents. We plan to initiate the AdAPT trial of oral brincidofovir for the treatment of adenovirus infection later this year,” continued Dr. Berrey.

Recent Highlights and Program Updates:

Initiated Multiple Ascending Dose Study of IV Brincidofovir

Chimerix commenced dosing in the multiple ascending dose (MAD) study of intravenous (IV) brincidofovir (BCV) in healthy subjects. This study is designed to evaluate the safety, tolerability and pharmacokinetics associated with multiple doses of IV BCV given once or twice weekly in healthy subjects. Data from this study will inform the continued development of this new formulation toward the planned Multi-Viral Prevention study of DNA viral infections in pediatric stem cell transplant recipients (MVP-Peds).

Additional Pipeline Updates

Study start-up activities are on-track for AdAPT, or Adenovirus after Allogeneic Pediatric Transplantation, previously referred to as Study 999. The Company is in active discussions with regulators on the final study design and intends to initiate AdAPT with short-course oral BCV later this year as previously communicated.

Development of BCV as a potential countermeasure for smallpox continues in collaboration with the Biomedical Advanced Research and Development Authority (BARDA). On Friday, Chimerix received correspondence from the FDA that indicated the Company will need to conduct a second rabbitpox study. The Company plans to seek clarification and is committed to work with the FDA and BARDA to gain agreement on next steps.

Chimerix anticipates initiation of a first-time-in-human (FTIH) study for CMX521 later this year. Identified from the Chimerix Chemical Library, CMX521 is a nucleoside analog, which targets the norovirus polymerase, a part of the virus which is required for viral replication and is common to all viral strains, including genetically diverse norovirus strains that have been associated with outbreaks.

Second Quarter 2017 Financial Results

Chimerix reported a net loss of $16.7 million, or $0.36 per basic and diluted share, for the second quarter of 2017. During the same period in 2016, Chimerix recorded a net loss of $18.1 million, or $0.39 per basic and diluted share.

Revenues for the second quarter of 2017 decreased to $0.7 million, compared to $1.8 million for the same period in 2016.

Research and development expenses decreased to $11.6 million for the second quarter of 2017, compared to $13.8 million for the same period in 2016.

General and administrative expenses decreased to $6.3 million for the second quarter of 2017, compared to $6.6 million for the same period in 2016.

Loss from operations was $17.2 million for the second quarter of 2017, compared to a loss from operations of $18.5 million for the same period in 2016.

Chimerix's balance sheet at June 30, 2017 included $251.5 million of capital available to fund operations, no debt, and approximately 47.0 million outstanding shares of common stock.

Today's Conference Call and Webcast

Chimerix will host a conference call and live audio webcast to discuss second quarter 2017 financial results and provide a business update today at 8:30 a.m. ET. To access the live conference call, please dial 877-354-4056 (domestic) or 678-809-1043 (international) at least five minutes prior to the start time and refer to conference ID 54730100.

A live audio webcast of the call will also be available on the Investors section of Chimerix's website, An archived webcast will be available on the Chimerix website approximately two hours after the event.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage compounds. In addition, Chimerix has in early-stage development a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website,

About Brincidofovir

Chimerix's lead product candidate, brincidofovir, is a nucleotide analog that has shown in vitro antiviral activity against all five families of DNA viruses that affect humans, including the herpes viruses and adenoviruses. Brincidofovir has a high barrier to resistance, no myelosuppression and low risk of nephrotoxicity. Brincidofovir has received Fast Track designation from the FDA for adenovirus, CMV and smallpox. Brincidofovir has also received Orphan Medicinal Product Designation from the European Commission for the treatment of adenovirus and for the prevention of CMV disease, and the Committee for Orphan Medicinal Products has issued a positive opinion for an Orphan Designation for the treatment of smallpox.

Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility that there may not be a viable continued development path for brincidofovir, that FDA and other regulatory authorities may not approve brincidofovir or brincidofovir-based regimens, that CMX521 may not demonstrate expected activity against norovirus, and that marketing approvals, if granted, may have significant limitations on their use. As a result, brincidofovir may never be successfully commercialized. In addition, Chimerix may be unable to file for regulatory approval for brincidofovir with other regulatory authorities. These risks, uncertainties and other factors could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in the Company's filings with the Securities and Exchange Commission, including without limitation the Company's most recent Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(in thousands, except share and per share data)
June 30, December 31,
2017 2016
Current assets:
Cash and cash equivalents $ 23,891 $ 51,463
Short-term investments, available-for-sale 124,637 180,558
Accounts receivable - 1,599
Prepaid expenses and other current assets 3,148 2,845
Total current assets 151,676 236,465
Long-term investments 103,643 47,407
Property and equipment, net of accumulated depreciation 2,306 2,843
Other long-term assets 51 55
Total assets $ 257,676 $ 286,770
Current liabilities:
Accounts payable $ 1,609 $ 3,890
Accrued liabilities 6,159 6,215
Total current liabilities 7,768 10,105
Lease-related obligations 246 441
Total liabilities 8,014 10,546
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized at June 30, 2017 and
December 31, 2016; no shares issued and outstanding as of June 30, 2017 and
December 31, 2016
Common stock, $0.001 par value, 200,000,000 shares authorized at June 30, 2017 and
December 31, 2016; 47,042,762 and 46,522,475 shares issued and outstanding as of
June 30, 2017 and December 31, 2016, respectively 47 46
Additional paid-in capital 701,329 692,442
Accumulated other comprehensive loss, net (1,475) (440)
Accumulated deficit (450,239) (415,804)
Total stockholders’ equity 249,662 276,244
Total liabilities and stockholders’ equity $ 257,676 $ 286,790

(in thousands, except share and per share data)
Three Months Ended June 30, Six Months Ended June 30,
2017 2016 2017 2016
Contract revenue $ 675 $ 1,841 $ 1,753 $ 3,069
Operating expenses:
Research and development 11,636 13,759 24,378 34,695
General and administrative 6,284 6,607 12,880 13,531
Total operating expenses 17,920 20,366 37,258 48,226
Loss from operations (17,245) (18,525) (35,505) (45,157)
Interest Income 565 377 1,071 749
Net loss (16,680) (18,148) (34,434) (44,408)
Other comprehensive loss:
Unrealized (loss) gain on investments, net (1,366) 75 (1,035) 496
Comprehensive loss $ (18,046) $ (18,073) $ (35,469) $ (43,912)
Per share information:
Net loss, basic and diluted $ (0.36) $ (0.39) $ (0.74) $ (0.96)
Weighted-average shares outstanding, basic and diluted 46,863,753 46,214,086 46,719,367 46,199,110

CONTACT: Investor Relations: or Will O’Connor Stern Investor Relations 212-362-1200 Media: Becky Vonsiatsky W2O Group 413-478-2003

Source:Chimerix, Inc.